Shannon N. Westin, MD, MPH, FACOG

Articles

FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer

August 15th 2024

Dr Westin discusses the FDA approval of durvalumab plus chemotherapy for patients with dMMR advanced or recurrent endometrial cancer.

Dr Westin on the FDA Approval of Durvalumab Plus Chemo in dMMR Endometrial Cancer

August 8th 2024

Shannon Westin, MD, MPH, FACOG, discusses the FDA approval of durvalumab plus chemotherapy in dMMR advanced or recurrent endometrial cancer.

Dr Westin on Early Findings With Azenosertib in High-Grade Serous Ovarian Cancer

April 11th 2024

Shannon N. Westin, MD, MPH, FACOG, discusses the DENALI trial of azenosertib in patients with high-grade serous ovarian cancer.

Future Outlook for Treatment of Endometrial Cancer

August 10th 2023

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

Ongoing Trials in Endometrial Cancer

August 10th 2023

An overview of ongoing research in the endometrial cancer treatment space.

KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer

August 3rd 2023

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.

The PHAEDRA Study and Clinical Trial Landscape in Endometrial Cancer

August 3rd 2023

A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.

NRG-GY018 and RUBY Trials in Endometrial Cancer

July 27th 2023

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

Recently Presented Data on Endometrial Cancer

July 27th 2023

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.

MIRASOL Trial: Mirvetuximab in Platinum-Resistant Ovarian Cancer

July 20th 2023

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.

Ongoing Trials on Maintenance Therapy in Recurrent Ovarian Cancer

July 20th 2023

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

July 13th 2023

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Efficacy of Subsequent Therapies in Advanced Ovarian Cancer

July 13th 2023

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

Recent Data on PARP Inhibitors as First-Line Maintenance in Ovarian Cancer

July 6th 2023

A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.

Unmet Needs in the Maintenance Setting in Ovarian Cancer

July 6th 2023

An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.

Ovarian Cancer: Deciding Between Treatment Options

June 29th 2023

Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.

Frontline Maintenance Therapy in Ovarian Cancer

June 29th 2023

A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.

Key Data Highlights in Ovarian Cancer

November 17th 2022

The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.

Treatment of Rare Tumors in Ovarian Cancer

November 17th 2022

Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.

Investigative Therapies in Recurrent Ovarian Cancer

November 10th 2022

A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.